| Unique ID issued by UMIN | UMIN000063701 |
|---|---|
| Receipt number | R000072856 |
| Scientific Title | Effects of Early Exercise Intervention in Older Patients with Colorectal Cancer Undergoing Oxaliplatin-Based Chemotherapy |
| Date of disclosure of the study information | 2026/11/19 |
| Last modified on | 2026/11/19 19:04:29 |
Home-Based Exercise and Chemotherapy adherence in Older Adults with Colorectal Cancer
Home-Based Exercise and Chemotherapy adherence in Older Adults with Colorectal Cancer
Effects of Early Exercise Intervention in Older Patients with Colorectal Cancer Undergoing Oxaliplatin-Based Chemotherapy
Early Exercise in Older Patients with Colorectal Cancer Receiving Oxaliplatin
| Japan |
colorectal cancer
| Rehabilitation medicine |
Malignancy
NO
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse effect of oxaliplatin-a key agent in the pharmacological treatment of colorectal cancer-and may impact the physical function of elderly patients as well as their ability to continue treatment. In this study, we conduct an exploratory analysis of the relationship between exercise intervention and chemotherapy adherence, utilizing data from a prior study that examined the feasibility of a home-based exercise program for elderly colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
Efficacy
Exploratory
Oxaliplatin relative dose intensity (RDI) during the first 3 months of treatment and the proportion of patients who maintained an RDI of 85% or higher.
Cumulative oxaliplatin dose, incidence of CIPN (Grade 2 or higher according to the Common Terminology Criteria for Adverse Events [CTCAE] v4.0), and modifications to the treatment plan due to peripheral neuropathy.
Observational
| 65 | years-old | <= |
| Not applicable |
Male and Female
Colorectal cancer patients who initiated oxaliplatin-based outpatient chemotherapy at NHO Tokyo Medical Center between 2019/1/1 and 2024/12/31.
Patients were excluded if they had difficulty communicating or were unable to understand the study purpose; had a history of prior chemotherapy associated with peripheral neurotoxicity; had neurological disorders (e.g., central nervous system diseases causing motor or sensory impairment) or psychiatric conditions; received only speech-language-hearing therapy; or had any condition deemed inappropriate for participation by the treating physician.
32
| 1st name | Motoyasu |
| Middle name | |
| Last name | Takenaka |
NHO Tokyo Medical Center
Department of Rehabilitation medicine
152-8902
2-5-1 Higashigaoka, Meguro-ku, Tokyo
0334110111
kuma1mie2chibi3@yahoo.co.jp
| 1st name | Chieko |
| Middle name | |
| Last name | Miyata |
NHO Tokyo Medical Center
Clinial Research Center
152-8902
2-5-1 Higashigaoka, Meguro-ku, Tokyo
0334110111
https://tokyo-mc.hosp.go.jp/wp-content/uploads/2025/05/R25-001.pdf
kuma1mie2chibi3@yahoo.co.jp
NHO Tokyo Medical Center
Japan Society for the Promotion of Science KAKENHI
Japanese Governmental office
Ethics Committee, National Hospital Organization Tokyo Medical Center
2-5-1 Higashigaoka, Meguro-ku, Tokyo
03-3411-2526
kuma1mie2chibi3@yahoo.co.jp
NO
| 2026 | Year | 11 | Month | 19 | Day |
Unpublished
32
No longer recruiting
| 2026 | Year | 02 | Month | 17 | Day |
| 2026 | Year | 03 | Month | 26 | Day |
| 2026 | Year | 04 | Month | 01 | Day |
| 2026 | Year | 08 | Month | 30 | Day |
| 2026 | Year | 08 | Month | 30 | Day |
| 2026 | Year | 08 | Month | 30 | Day |
| 2026 | Year | 09 | Month | 30 | Day |
This retrospective, comparative, secondary analysis included older patients with colorectal cancer receiving oxaliplatin-based chemotherapy who had participated in a 12-week home-based exercise program in a prospective feasibility study, as well as a historical usual-care control group.
| 2026 | Year | 11 | Month | 19 | Day |
| 2026 | Year | 11 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072856